Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15608674rdf:typepubmed:Citationlld:pubmed
pubmed-article:15608674lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C0005684lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C0021549lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C2700185lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C1334148lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:15608674lifeskim:mentionsumls-concept:C1706701lld:lifeskim
pubmed-article:15608674pubmed:issue8lld:pubmed
pubmed-article:15608674pubmed:dateCreated2005-2-17lld:pubmed
pubmed-article:15608674pubmed:abstractTextTo investigate the molecules that regulate the acquisition of cis-diamminedichloroplatinum (II) (cisplatin) resistance, we performed cDNA microarrays using two pairs of parental and cisplatin-resistant bladder cancer cell lines. We found a markedly reduced expression of inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1), endoplasmic reticulum membrane protein, in cisplatin-resistant cells. The suppression of IP3R1 expression using small interfering RNA in parental cells prevented apoptosis and resulted in decreased sensitivity to cisplatin. Contrarily, overexpression of IP3R1 in resistant cells induced apoptosis and increased sensitivity to cisplatin. These results suggest that cisplatin-induced downregulation of IP3R1 expression was closely associated with the acquisition of cisplatin resistance in bladder cancer cells.lld:pubmed
pubmed-article:15608674pubmed:languageenglld:pubmed
pubmed-article:15608674pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:citationSubsetIMlld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15608674pubmed:statusMEDLINElld:pubmed
pubmed-article:15608674pubmed:monthFeblld:pubmed
pubmed-article:15608674pubmed:issn0950-9232lld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:HirataAkiraAlld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:YokomizoAkira...lld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:KogaHirofumiHlld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:NaitoSeijiSlld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:OkumuraKojiKlld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:EtoMasatoshiMlld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:TsunodaToshiy...lld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:InokuchiJunic...lld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:MasudaKatsuak...lld:pubmed
pubmed-article:15608674pubmed:authorpubmed-author:TatsugamiKats...lld:pubmed
pubmed-article:15608674pubmed:issnTypePrintlld:pubmed
pubmed-article:15608674pubmed:day17lld:pubmed
pubmed-article:15608674pubmed:volume24lld:pubmed
pubmed-article:15608674pubmed:ownerNLMlld:pubmed
pubmed-article:15608674pubmed:authorsCompleteYlld:pubmed
pubmed-article:15608674pubmed:pagination1396-402lld:pubmed
pubmed-article:15608674pubmed:dateRevised2007-7-18lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:meshHeadingpubmed-meshheading:15608674...lld:pubmed
pubmed-article:15608674pubmed:year2005lld:pubmed
pubmed-article:15608674pubmed:articleTitleInositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines.lld:pubmed
pubmed-article:15608674pubmed:affiliationDepartment of Urology, Graduate School of Medical Sciences, Kyushu University 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.lld:pubmed
pubmed-article:15608674pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15608674pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15608674lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15608674lld:pubmed